Surrogate Endpoint ‘Reasonably Likely’ Decision Process An ‘Uncertain Standard,’ Industry Says

 
• By Sue Sutter
  
Question mark
The FDA's accelerated approval draft guidance describes an "uncertain standard" for identifying acceptable endpoints, PhRMA said. (Shutterstock)

More from Review Pathways

More from Pathways & Standards